BR112019003032A2 - inibidores de invasão intracelular - Google Patents

inibidores de invasão intracelular

Info

Publication number
BR112019003032A2
BR112019003032A2 BR112019003032A BR112019003032A BR112019003032A2 BR 112019003032 A2 BR112019003032 A2 BR 112019003032A2 BR 112019003032 A BR112019003032 A BR 112019003032A BR 112019003032 A BR112019003032 A BR 112019003032A BR 112019003032 A2 BR112019003032 A2 BR 112019003032A2
Authority
BR
Brazil
Prior art keywords
invasion inhibitors
intracellular invasion
periodontitis
intracellular
inhibitors
Prior art date
Application number
BR112019003032A
Other languages
English (en)
Inventor
Chen Chin-Ho
Xie Hua
Original Assignee
Univ Duke
Meharry Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke, Meharry Medical College filed Critical Univ Duke
Publication of BR112019003032A2 publication Critical patent/BR112019003032A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Food Science & Technology (AREA)

Abstract

a presente invenção refere-se a compostos que inibem a invasão de células hospedeiras por parasitas intracelulares. esta encontra uso, por exemplo, no tratamento e prevenção de periodontite ou uma condição relacionada a periodontite ou sintoma.
BR112019003032A 2016-08-18 2017-08-18 inibidores de invasão intracelular BR112019003032A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662376756P 2016-08-18 2016-08-18
PCT/US2017/047677 WO2018035497A1 (en) 2016-08-18 2017-08-18 Inhibitors of intracellular invasion

Publications (1)

Publication Number Publication Date
BR112019003032A2 true BR112019003032A2 (pt) 2019-05-14

Family

ID=61197110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019003032A BR112019003032A2 (pt) 2016-08-18 2017-08-18 inibidores de invasão intracelular

Country Status (5)

Country Link
US (2) US11123333B2 (pt)
BR (1) BR112019003032A2 (pt)
EA (1) EA201990491A1 (pt)
MX (1) MX2019001770A (pt)
WO (1) WO2018035497A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86596A1 (fr) * 1986-09-17 1988-04-05 Oreal Gel dentifrice
CN102688240A (zh) * 2012-05-18 2012-09-26 广州军区广州总医院 一种治疗结直肠癌的药物组合物
JP2014047157A (ja) * 2012-08-30 2014-03-17 Kitasato Institute 口腔用殺菌組成物
KR20140086704A (ko) * 2012-12-28 2014-07-08 울산대학교 산학협력단 디나소어를 포함하는 퇴행성 신경질환 예방 또는 치료용 약학 조성물
CN105770999B (zh) * 2016-03-03 2019-01-29 宁夏大学 一种消除细菌生物被膜的复合生物材料

Also Published As

Publication number Publication date
WO2018035497A1 (en) 2018-02-22
US11123333B2 (en) 2021-09-21
US20210379030A1 (en) 2021-12-09
EA201990491A1 (ru) 2019-08-30
MX2019001770A (es) 2019-12-05
US20190175565A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
CY1120988T1 (el) Παρεμποδιστες διαρυλ κινασης
CO2018010459A2 (es) Composiciones que comprenden cepas bacterianas
BR112018004620A2 (pt) moduladores da expressão de kras
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
BR112018003588A2 (pt) compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
UY35821A (es) Compuesto heterocíclico
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
MX2019000088A (es) Composiciones y metodos para detectar y tratar la diabetes.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112017028194A2 (pt) moduladores de diaciglicerol aciltransferase 2 (dgat2)
BR112016026544A2 (pt) métodos para inibir a necroptose
BR112017006368A2 (pt) derivados de ácido borônico
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
CO2018009677A2 (es) Sulfonamidas sustituidas para controlar plagas animales
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
MX2017005249A (es) Compuestos para usarse en el tratamiento antihelmintico.
BR112018014247A2 (pt) inibição de reação alérgica usando um inibidor il-33
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
TR201906418T4 (tr) Solüsyonlarda 1-metilsiklopropenin stabilize edilmesine yönelik bileşimler ve yöntemler.
BR112016025278A2 (pt) composições dentifrícias com estabilidade de íon fluoreto ou absorção de fluoreto melhoradas
MX2017001047A (es) Compuestos para usar en el tratamiento antihelmintico.
CL2016001977A1 (es) Composición que comprende igm derivada de plasma y su uso para el tratamiento o prevención de afecciones inmunitarias.
CY1124229T1 (el) Συνδυασμος τραζοδονης και γκαμπαπεντινης για την αντιμετωπιση του πονου

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]